Click here to read the Cover Story, “Specialists navigate changing, challenging landscape of geographic atrophy management.”
Geographic atrophy management could benefit greatly from the combination of novel therapies and AI-driven imaging technology.
However, while our U.S. colleagues have FDA-approved complement inhibitors available but no tools, in Europe, we have approved tools, namely the RetInSight/Topcon GA Monitor, but not the treatments. While we wait to hopefully have access to both in Europe and the U.S., how can we take best advantage of this situation?
Obviously, we can provide